Testimonials

We are grateful for testimonial support from a wide range of pharma and investors, as well as public and private biotech and medtech R&D companies from all around the world.  All testimonials are published with kind permission from their authors.

Testimonials

As always the premier biotechnology conference in Europe for investors to attend. An excellent range of companies and investors present.
Carlos Pittol, Director, Clubb Capital Ltd
An excellent event bringing together the best from venture capital, innovators and industry.
Aris Constantinides, Investment Director, NBGI Private Equity Limited
We were delighted to meet ViraTherapeutics for the first time in a one-to-one partnering meeting at BioTrinity 2014. As an emerging Austrian biotech company, ViraTherapeutics develop a differentiated oncolytic virotherapy, into which we and EBML Ventures went on to lead a €3.6m investment which was announced shortly after BioTrinity 2015
Detlev Mennerich, Investment Manager, Boehringer Ingelheim Venture Fund (BIVF) (Germany)
BioTrinity is now Europe's premier life science partnering conference, and is firmly established as the 'must go to' conference for anyone seriously involved in early stage therapeutic innovation
Graeme Martin, President & CEO, Takeda Ventures (USA)
The partnering event at BioTrinity was well organized, effective and provided significant value to me and QureTech Bio. This event was clearly worth an overseas trip even for an early stage biotech company!
Fritiof Pontén, CEO, QureTech Bio AB (Sweden)
I attended BioTrinity in 2016 for the first time and it was simply amazing how many opportunities this conference provided to meet and engage people interested in ongoing activities at Eudendron. I would suggest to attend BioTrinity to those people looking for funding opportunities to advance their project or companies within the life sciences sector.
Mauro Angiolini, Managing Director, Eudendron Srl
"BioTrinity has the charisma to motivate entrepreneurs, investors and scientists from Europe's top biotech and healthcare clusters to collect in one place. It's the gateway to European biotech."
Simon Haworth, Founder, Dynasty Biotechnology & The Sino-UK Fund
BioTrinity 2016, as Europe’s leading investment and biopartnering conference, was a great opportunity for Sanofi to increase our visibility as a partner of choice in bringing therapeutic advances and hope to patients around the world
Yvonne Naughton, Head of Business Development and New Product Planning,Sanofi
An essential event in our annual calendar, BioTrinity allows networking with industry leaders, informative panel discussions and a well attended exhibition.
Vicky Steadman, Director of Discovery, Selcia Ltd.
BioTrinity was an excellent forum in which to meet business development representatives of major companies, and at which to market our products and services.
Malcolm Young, CEO, e-Therapeutics Ltd
BioTrinity truly deserves the accolade of Europe’s leading investment and biopartnering conference. The diversity of participants, high attendance levels of key decision makers and the ease of arranging meetings make it a crucial event on our calendar.
Lisa Evans, Life Science Insurance Advisor, Arthur J Gallagher